Compile Data Set for Download or QSAR
Report error Found 822 with Last Name = 'stegmann' and Initial = 'c'
TargetProtein arginine N-methyltransferase 6(Human)
University of Toronto

Curated by ChEMBL
LigandPNGBDBM50158094(CHEMBL3780926)
Affinity DataKd:  970nMAssay Description:Binding affinity to Inhibition of N-terminal hexa-His tagged human PRMT6 expressed in Sf9 cells by ITC methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/17/2017
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395298(6-(Difluoromethyl)-N-[2-(3-hydroxy-3-methylbutyl)-...)
Affinity DataIC50: 1.30nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395298(6-(Difluoromethyl)-N-[2-(3-hydroxy-3-methylbutyl)-...)
Affinity DataIC50: 1.30nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395298(6-(Difluoromethyl)-N-[2-(3-hydroxy-3-methylbutyl)-...)
Affinity DataIC50: 1.30nMAssay Description:The IRAK4-inhibitory activity of the inventive substances was measured in the IRAK4 TR-FRET assay (TR-FRET=Time Resolved Fluorescence Resonance Energ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/21/2024
Entry Details
Go to US Patent

TargetAldo-keto reductase family 1 member C3/Glutathione S-transferase P(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258453(US9512169, 7)
Affinity DataIC50: 1.40nMpH: 7.0 T: 2°CAssay Description:For the assay, 50 nl of a 100-fold concentrated solution of the test substance in DMSO were pipetted into a black low-volume 384-well microtiter plat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetAldo-keto reductase family 1 member C3/Glutathione S-transferase P(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258457(US9512169, 11)
Affinity DataIC50: 2.5nMpH: 7.0 T: 2°CAssay Description:For the assay, 50 nl of a 100-fold concentrated solution of the test substance in DMSO were pipetted into a black low-volume 384-well microtiter plat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetAldo-keto reductase family 1 member C3/Glutathione S-transferase P(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258456(US9512169, 10)
Affinity DataIC50: 2.70nMpH: 7.0 T: 2°CAssay Description:For the assay, 50 nl of a 100-fold concentrated solution of the test substance in DMSO were pipetted into a black low-volume 384-well microtiter plat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetAldo-keto reductase family 1 member C3/Glutathione S-transferase P(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258459(US9512169, 13)
Affinity DataIC50: 2.80nMpH: 7.0 T: 2°CAssay Description:For the assay, 50 nl of a 100-fold concentrated solution of the test substance in DMSO were pipetted into a black low-volume 384-well microtiter plat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395296(N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-...)
Affinity DataIC50: 3.40nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395296(N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-...)
Affinity DataIC50: 3.40nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395296(N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-...)
Affinity DataIC50: 3.40nMAssay Description:The IRAK4-inhibitory activity of the inventive substances was measured in the IRAK4 TR-FRET assay (TR-FRET=Time Resolved Fluorescence Resonance Energ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/21/2024
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395307(N-{2-[2-(1-Hydroxycyclopropyl)ethyl]-6-(2-hydroxyp...)
Affinity DataIC50: 3.70nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395307(N-{2-[2-(1-Hydroxycyclopropyl)ethyl]-6-(2-hydroxyp...)
Affinity DataIC50: 3.70nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395307(N-{2-[2-(1-Hydroxycyclopropyl)ethyl]-6-(2-hydroxyp...)
Affinity DataIC50: 3.70nMAssay Description:The IRAK4-inhibitory activity of the inventive substances was measured in the IRAK4 TR-FRET assay (TR-FRET=Time Resolved Fluorescence Resonance Energ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/21/2024
Entry Details
Go to US Patent

TargetAldo-keto reductase family 1 member C3/Glutathione S-transferase P(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258458(US9512169, 12)
Affinity DataIC50: 4nMpH: 7.0 T: 2°CAssay Description:For the assay, 50 nl of a 100-fold concentrated solution of the test substance in DMSO were pipetted into a black low-volume 384-well microtiter plat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298092(US10118930, Example 302 | 3-[3-(2-tert-butoxyethyl...)
Affinity DataIC50: 6nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395288(N-[6-(2-Hydroxypropan-2-yl)-2-(3-methoxypropyl)-2H...)
Affinity DataIC50: 7.20nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395288(N-[6-(2-Hydroxypropan-2-yl)-2-(3-methoxypropyl)-2H...)
Affinity DataIC50: 7.20nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395288(N-[6-(2-Hydroxypropan-2-yl)-2-(3-methoxypropyl)-2H...)
Affinity DataIC50: 7.20nMAssay Description:The IRAK4-inhibitory activity of the inventive substances was measured in the IRAK4 TR-FRET assay (TR-FRET=Time Resolved Fluorescence Resonance Energ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/21/2024
Entry Details
Go to US Patent

TargetAldo-keto reductase family 1 member C3/Glutathione S-transferase P(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258447(US9512169, 1)
Affinity DataIC50: 7.60nMpH: 7.0 T: 2°CAssay Description:For the assay, 50 nl of a 100-fold concentrated solution of the test substance in DMSO were pipetted into a black low-volume 384-well microtiter plat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298254(US10118930, Example 452 | 3-(2-methylbutanoyl)-7-(...)
Affinity DataIC50: 8nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298255(US10118930, Example 453 | 3-(cyclopropylcarbonyl)-...)
Affinity DataIC50: 8nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetAldo-keto reductase family 1 member C3/Glutathione S-transferase P(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258447(US9512169, 1)
Affinity DataIC50: 8nMpH: 7.0 T: 2°CAssay Description:For the assay, 50 nl of a 100-fold concentrated solution of the test substance in DMSO were pipetted into a black low-volume 384-well microtiter plat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298041(US10118930, Example 253 | 3-(2-methyl-1,3-thiazol-...)
Affinity DataIC50: 8.20nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetAldo-keto reductase family 1 member C3/Glutathione S-transferase P(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258449(US9512169, 3)
Affinity DataIC50: 8.60nMpH: 7.0 T: 2°CAssay Description:For the assay, 50 nl of a 100-fold concentrated solution of the test substance in DMSO were pipetted into a black low-volume 384-well microtiter plat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297950(US10118930, Example 166 | 7-(piperidin-4-yl)-3-{5-...)
Affinity DataIC50: 8.70nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395304(5-Fluoro-N-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydro...)
Affinity DataIC50: 8.90nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395304(5-Fluoro-N-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydro...)
Affinity DataIC50: 8.90nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395304(5-Fluoro-N-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydro...)
Affinity DataIC50: 8.90nMAssay Description:The IRAK4-inhibitory activity of the inventive substances was measured in the IRAK4 TR-FRET assay (TR-FRET=Time Resolved Fluorescence Resonance Energ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/21/2024
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298115(US10118930, Example 327 | 7-(piperidin-4-yl)-3-(pi...)
Affinity DataIC50: 9nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298123(US10118930, Example 335 | 3-(4-cyclohexyl-1,3-thia...)
Affinity DataIC50: 9nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetAldo-keto reductase family 1 member C3/Glutathione S-transferase P(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258452(US9512169, 6)
Affinity DataIC50: 9.20nMpH: 7.0 T: 2°CAssay Description:For the assay, 50 nl of a 100-fold concentrated solution of the test substance in DMSO were pipetted into a black low-volume 384-well microtiter plat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298009(US10118930, Example 224 | 3-[3-(4-fluorobenzyl)-1,...)
Affinity DataIC50: 9.70nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290292(US10098883, Example 53 | 2-Oxo-4-(piperidin-4-yl)-...)
Affinity DataIC50: 10nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298073(US10118930, Example 283 | 3-[5-(2-phenylethyl)-1,3...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298184(US10118930, Example 387 | Rel-3-{5-[(1R,2S)-2-meth...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298237(US10118930, Example 437 | 3-[3-(2-methoxyphenyl)-1...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298246(US10118930, Example 446 | 3-[3-(4-hydroxybenzyl)-1...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetAldo-keto reductase family 1 member C3/Glutathione S-transferase P(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258464(US9512169, 18)
Affinity DataIC50: 10nMpH: 7.0 T: 2°CAssay Description:For the assay, 50 nl of a 100-fold concentrated solution of the test substance in DMSO were pipetted into a black low-volume 384-well microtiter plat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290292(US10098883, Example 53 | 2-Oxo-4-(piperidin-4-yl)-...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395297(N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)...)
Affinity DataIC50: 10.7nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395297(N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)...)
Affinity DataIC50: 10.7nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395297(N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)...)
Affinity DataIC50: 10.7nMAssay Description:The IRAK4-inhibitory activity of the inventive substances was measured in the IRAK4 TR-FRET assay (TR-FRET=Time Resolved Fluorescence Resonance Energ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/21/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395299(6-(Difluoromethyl)-N-{6-(2-hydroxypropan-2-yl)-2-[...)
Affinity DataIC50: 10.8nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395299(6-(Difluoromethyl)-N-{6-(2-hydroxypropan-2-yl)-2-[...)
Affinity DataIC50: 10.8nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395299(6-(Difluoromethyl)-N-{6-(2-hydroxypropan-2-yl)-2-[...)
Affinity DataIC50: 10.8nMAssay Description:The IRAK4-inhibitory activity of the inventive substances was measured in the IRAK4 TR-FRET assay (TR-FRET=Time Resolved Fluorescence Resonance Energ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/21/2024
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290334(US10098883, Example 77 | 9-Fluoro-10-phenyl-4-(pip...)
Affinity DataIC50: 11nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2019
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290336(US10098883, Example 79 | 10-Chloro-8-methyl-4-(pip...)
Affinity DataIC50: 11nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297791(US10118930, Example 16 | Ethyl 5-oxo-7-(piperidin-...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297845(US10118930, Example 68 | 5-[5-Oxo-7-(piperidin-4-y...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 822 total ) | Next | Last >>
Jump to: